Can a biologic drug quiet the relentless itch of prurigo nodularis?

NCT ID NCT06087627

Ongoing Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study follows adults with moderate-to-severe prurigo nodularis—a skin condition marked by intensely itchy nodules—who are starting treatment with dupilumab (Dupixent) as part of their normal care. Researchers will track how well the drug reduces itching and clears skin lesions over six months, along with its safety and impact on quality of life. Because it is an observational study, participants receive the drug as prescribed by their doctor, and no experimental treatment is provided.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dupilumab (Dupixent), a biologic drug given by injection
What this could lead to: If successful, this study could provide real-world evidence on how well dupilumab controls itching and skin lesions in prurigo nodularis over time, potentially supporting its broader use.
What could go wrong: As an observational study, it cannot prove cause and effect, and results may be influenced by patient selection or missing data. Long-term safety and effectiveness in routine practice may differ from clinical trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRURIGO NODULARIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prurigo nodularis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRURIGO NODULARIS

Contacts and locations

Locations

Investigational Site Number: 002

Berlin, 13507, Germany
Investigational Site Number: 004

Düsseldorf, 40219, Germany
Investigational Site Number: 005

Düren, 52349, Germany
Investigational Site Number: 007

Hamburg, 22391, Germany
Investigational Site Number: 013

Adernach, 56626, Germany
Investigational Site Number: 016

Leipzig, 04371, Germany
Investigational Site Number: 022

Potsdam, 14467, Germany
Investigational Site Number: 023

Chemnitz, 09117, Germany
Investigational Site Number: 024

Potsdam, 14469, Germany
Investigational Site Number: 031

Mainz, 55128, Germany
Investigational site number: 001

Berlin, 12203, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.